GROSS LAW FIRM

Odonate Therapeutics, Inc. Loss Submission Form

The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Southern District of California on behalf of shareholders of Odonate Therapeutics, Inc. who purchased shares between December 7, 2017 and April 21, 2020.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until November 16, 2020 to request that the court appoint them lead plaintiff.

To receive more information, please fill out the form.

The Gross Law Firm does not share your information with others. There is no other or obligation for you to submit.

Name

Email

Physical Address

Phone Number

Shares Owned

Purchase Date

Loss

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.